Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Alacepril [INN:JAN]
RN: 74258-86-9
UNII: X39TL7JDPF
InChIKey: FHHHOYXPRDYHEZ-COXVUDFISA-N

Classification Codes

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Enzyme Inhibitors
  • Hypertensive
  • Protease Inhibitors
  • Reproductive Effect

Molecular Formula

  • C20-H26-N2-O5-S

Molecular Weight

  • 406.5
 
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Alacepril
  • Alacepril [INN:JAN]

Synonyms

  • 1-(D-3-Acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine
  • Alacepril
  • Alaceprilum
  • Alaceprilum [Latin]
  • BRN 3634372
  • Cetapril
  • DU 1219
  • N-(1-((S)-3-Mercapto-2-methylpropionyl)-L-prolyl)-3-phenyl-L-alanine acetate (ester)
  • N-(2-((S)-3-Acetylthio-2-methylpropionyl)propyl)-3-phenylalanin
  • NSC 338157
  • UNII-X39TL7JDPF

Systematic Names

  • L-Phenylalanine, N-(1-(3-(acetylthio)-2-methyl-1-oxopropyl)-L-prolyl)-, (S)-
  • N-(1-((S)-3-Mercapto-2-methylpropionyl)-L-prolyl)-3-phenyl-L-alanine acetate (ester)

Registry Numbers

CAS Registry Number

  • 74258-86-9

FDA UNII

  • X39TL7JDPF

System Generated Number

  • 0074258869

Structure Descriptors

InChI

1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1

InChIKey

FHHHOYXPRDYHEZ-COXVUDFISA-N

Smiles

C1CN([C@@H](C1)C(N[C@H](C(=O)O)Cc1ccccc1)=O)C([C@@H](CSC(C)=O)C)=O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral > 1600mg/kg (1600mg/kg)   Drugs in Japan Vol. -, Pg. 64, 1990.
mouse LD50 intraperitoneal 2921mg/kg (2921mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: CYANOSIS
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
mouse LD50 intravenous > 1gm/kg (1000mg/kg)   European Patent Application. Vol. #7477,
mouse LD50 oral > 5gm/kg (5000mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
mouse LD50 subcutaneous > 3gm/kg (3000mg/kg) SKIN AND APPENDAGES (SKIN): HAIR: OTHER

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
rat LD50 intraperitoneal 1872mg/kg (1872mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: CYANOSIS
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
rat LD50 oral > 5gm/kg (5000mg/kg) BEHAVIORAL: FOOD INTAKE (ANIMAL)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
rat LD50 subcutaneous > 3gm/kg (3000mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 13, Pg. 7033, 1985.
women TDLo oral 120mg/kg/17W- (120mg/kg) BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Internal Medicine. Vol. 38, Pg. 164, 1999.